infected each year, reducing incidence of HPV in the general population could affect disease transmission as well as cancer rates. "There's pretty good evidence that men are a reservoir for HPV and are vectors for it," said James Turner, M.D., professor of clinical internal medicine at the University of Virginia and chair of the Vaccine Preventable Disease Committee for the American College Health Association. "Protection makes sense, particularly if you can vaccinate boys before they become sexually active."
If the FDA approves the vaccine for males, the CDC's Advisory Committee on Immunization Practices (ACIP) will also review the data and recommend how the vaccine should be used. The ACIP recommendation will be important because it serves as a guideline for primary care providers. "Certainly if the ACIP recommends the HPV vaccine at age 11, it will be adopted by pediatricians and family practitioners," Turner said. "They'll recommend it when families come in."
For women, the ACIP recommended that the Gardasil vaccine target girls aged 9 -11 years, with catch-up vaccination recommended between ages 12 and 26 years. Merck hopes that the same will be true for males.
"The goal is for boys to be protected from something that can be prevented," Ogden said. "And the incidence of genital lesions is high for boys."
Marketing Challenge
If Gardasil were made available to males, the strongest push to vaccinate would probably come from family physicians and wellinformed parents, according to Brigitte Miller, M.D., section head of gynecologic oncology at the Comprehensive Cancer Center of Wake Forest University in Winston-Salem, N.C. This has been true for Gardasil use in women.
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But marketing Gardasil to men could prove more challenging than marketing it to women. With more than 11,000 new cases diagnosed each year in the U.S. and more than 3,000 deaths, cervical cancer is more widespread than penile or anal cancers.
Also, HPV-related cancers often occur in older men -between ages 50 and 80 years -who carry the virus for decades; in women, precancerous changes can show up on a pap test within 2 -4 years of being infected and, if they are persistent and go untreated, can develop into cervical cancer when a woman is in her 30s or 40s.
"I think vaccinating adolescent males will signifi cantly impact the transmission of the disease," Turner said. "But it will be hard to convince … males to get the vaccine."
However, there is already strong interest in the HPV vaccine among special populations, including college-aged men, gay men, and women older than 26 years, according to Laurie Markowitz, M.D., an epidemiologist and head of the HPV working group at the CDC. Doctors report several cases of off-label Gardasil use.
"For women it has been a simpler conversation to talk about a vaccine that can protect you against cervical cancer," said Rachel Katzenellenbogen, M.D., assistant professor of pediatrics at the University of Washington and Seattle Children's Hospital. "But a lot of people are excited about it [becoming available for men] and are waiting for it."
If Gardasil receives a broad recommendation for use in males from the CDC, the uptake trajectory of the vaccine could mirror that of females, with about 25% of the population getting vaccinated. This is a typical pattern for vaccines that are not mandatory for school attendance, such as the chickenpox and the MMR (measlesmumps -rubella) vaccines. Although about 20 states have proposed legislature to mandate Gardasil vaccine use in adolescent girls, it is unclear whether it ever will be made mandatory for all school children. Mandated vaccines are typically for diseases that are equally distributed and highly communicable, something that can be spread by coughing or sneezing, for example. There are mandatory vaccines for noncommunicable diseases, such as tetanus, but those are ubiquitous and are diseases that children are susceptible to.
"This vaccine is different from the other vaccines we accept mandates for in that your risk is infl uenced by your behavior and is not equally distributed," said Gail Javitt, J.D., a research scholar with the Berman Institute of Bioethics at Johns Hopkins University, Baltimore.
Research and literature on HPV has been heavily weighted toward women because they bear much of the disease burden. But now, researchers say, the fi eld may expand. "It opens the door now to look at whether the vaccine could also prevent [infection at] other sites where we know HPV causes cancer," Giuliano said, including oropharyngeal cancers as a result of HPV transmitted during oral sex. "The rationale to move forward now is pretty strong."
